{
    "ticker": "RZLT",
    "name": "Rezolute, Inc.",
    "description": "Rezolute, Inc. is a biotechnology company focused on developing innovative therapies for rare and life-threatening diseases, particularly in the field of metabolic and ophthalmic disorders. Founded in 2015 and headquartered in Fort Lee, New Jersey, Rezolute is dedicated to addressing unmet medical needs through its proprietary drug development programs. The company's lead product candidate, RZ358, is being developed for the treatment of congenital hyperinsulinism, a rare condition that causes severe hypoglycemia in infants and young children. Rezolute aims to enhance the lives of patients by advancing therapies that target the underlying causes of disease rather than just managing symptoms. With a strong emphasis on research and development, the company collaborates with leading academic institutions and clinical research organizations to drive innovation and expedite the clinical development process. Rezolute's mission is to bring transformative therapies to market that can make a significant difference in the lives of patients suffering from rare diseases.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Fort Lee, New Jersey, USA",
    "founded": "2015",
    "website": "https://www.rezolutebio.com",
    "ceo": "Neal M. K. R. S. M. V. B. P. G. P. C. T. K. R. M. M. K. R. C. T. K. M. K. R. T. K. R. M. K.",
    "social_media": {
        "twitter": "https://twitter.com/rezolutebio",
        "linkedin": "https://www.linkedin.com/company/rezolute/"
    },
    "investor_relations": "https://www.rezolutebio.com/investor-relations",
    "key_executives": [
        {
            "name": "Neal M. K. R. S. M. V. B. P. G. P. C. T. K. R. M. M. K. R. C. T. K. M. K. R. T. K. R. M. K.",
            "position": "CEO"
        },
        {
            "name": "David M. Z. H. C. K. R. M.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "RZ358"
            ]
        }
    ],
    "seo": {
        "meta_title": "Rezolute, Inc. | Innovative Therapies for Rare Diseases",
        "meta_description": "Discover Rezolute, Inc., a biotechnology company focused on developing transformative therapies for rare diseases. Learn about our innovative drug development programs and mission.",
        "keywords": [
            "Rezolute",
            "Biotechnology",
            "Pharmaceuticals",
            "RZ358",
            "Rare Diseases",
            "Metabolic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Rezolute known for?",
            "answer": "Rezolute is known for developing innovative therapies for rare and life-threatening diseases."
        },
        {
            "question": "Who is the CEO of Rezolute?",
            "answer": "Neal M. K. R. S. M. V. B. P. G. P. C. T. K. R. M. M. K. R. C. T. K. M. K. R. T. K. R. M. K. is the CEO of Rezolute, Inc."
        },
        {
            "question": "Where is Rezolute headquartered?",
            "answer": "Rezolute is headquartered in Fort Lee, New Jersey, USA."
        },
        {
            "question": "What is Rezolute's main product?",
            "answer": "Rezolute's main product candidate is RZ358, aimed at treating congenital hyperinsulinism."
        },
        {
            "question": "When was Rezolute founded?",
            "answer": "Rezolute was founded in 2015."
        }
    ],
    "competitors": [
        "RGEN",
        "PFE",
        "BMRN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}